NCT05980806Phase 2Recruiting

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Study sponsor: Karyopharm Therapeutics Inc · KPTI

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-06Estimated

Enrollment · participants58Estimated

Source updated2026-02-12Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-02-12 · 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Proportion of Participants with Spleen Volume Reduction 35 (SVR35) at Week 24.

+ After

Measure: Proportion of Participants with Spleen Volume Reduction ≥35% (SVR35) at Week 24

Planned enrollment decreased by 60 participants

− Before

~~118 participants (planned)~~

+ After

58 participants (planned)

Primary completion date changed

− Before

~~Apr 2026~~

+ After

Jun 2027

Check registry source

Study details

Conditions studied

Myelofibrosis; Moderate Thrombocytopenia; Mild Thrombocytopenia

Treatments or interventions studied

Selinexor 60 mgDrugAlso known as KPT-330
Selinexor 40 mgDrugAlso known as KPT-330
RuxolitinibDrugAlso known as JAKAFI
PacritinibDrugAlso known as VONJO
MomelotinibDrugAlso known as OJJAARA

Primary outcomes · main study measures

measure: Proportion of Participants with Spleen Volume Reduction ≥35% (SVR35) at Week 24; description: Measured by Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan by Investigator assessment.; timeFrame: At Week 24

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history